Type II Diabetes

Metabolic Diseases
1
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
Metformin HCL 500 mg Extended-Release Tablets, Geneva PTCPhase 11 trial
Active Trials
NCT00882882CompletedEst. Jun 2001
QT
Q TherapeuticsUT - Salt Lake City
1 program
Brown seaweedN/A1 trial
Active Trials
NCT04715776UnknownEst. Feb 2021
Fractyl Health
Fractyl HealthMA - Burlington
1 program
Fractyl Duodenal Remodeling SystemN/A1 trial
Active Trials
NCT01927562CompletedEst. Mar 2018
Sanofi
SanofiPARIS, France
1 program
Intensive discharge interventionN/A1 trial
Active Trials
NCT02122926Completed180Est. Jul 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozMetformin HCL 500 mg Extended-Release Tablets, Geneva PTC
Q TherapeuticsBrown seaweed
Fractyl HealthFractyl Duodenal Remodeling System
SanofiIntensive discharge intervention

Clinical Trials (4)

Total enrollment: 180 patients across 4 trials

NCT00882882SandozMetformin HCL 500 mg Extended-Release Tablets, Geneva PTC

To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions

Start: Jun 2001Est. completion: Jun 2001
Phase 1Completed
NCT04715776Q TherapeuticsBrown seaweed

Supplementation of Brown Seaweed on Insulin Resistance of NAFLD Patients With Pre- or Type 2-Diabetes

Start: Dec 2018Est. completion: Feb 2021
N/AUnknown
NCT01927562Fractyl HealthFractyl Duodenal Remodeling System

Initial Clinical Evaluation of an Endoscopic Therapy for Type 2 Diabetes

Start: Jul 2013Est. completion: Mar 2018
N/ACompleted
NCT02122926SanofiIntensive discharge intervention

Intensive Discharge Intervention in Diabetes

Start: Dec 2011Est. completion: Jul 2013180 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Manager, Patient Safety and Pharmacovigilance Operations

Kailera Therapeutics
Waltham, Massachusetts
8h ago

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
Yesterday

(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)

Johnson & Johnson
Beerse, Antwerp, Belgium
2d ago

Computational Chemist

Topos Bio
San Francisco Office
2d ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr

Application & Integration Architect

Roche
Indianapolis
5d ago
$106K - $196K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

Related Indications

Diabetes(737)Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes(207)Type 2 Diabetes Mellitus(190)Diabetes Mellitus(127)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)